What the question is asking
A federal cap on insulin would set a legal ceiling — often discussed as $35 per month — on what patients pay out of pocket, or in some proposals on what manufacturers can charge. The federal government already imposes such a cap for one group of patients (Medicare beneficiaries) but not for the broader insurance market.
How insulin is priced today
A 2022 RAND Corporation study found the average U.S. list price of insulin was about $98 per unit in 2018, compared with $7.52 in the United Kingdom and roughly $12 in Canada. List prices do not always reflect what patients or insurers actually pay after rebates and discounts, but out-of-pocket costs in the U.S. have nonetheless drawn bipartisan attention.
What Congress has already done
The Inflation Reduction Act of 2022 capped insulin copays at $35 per month for people enrolled in Medicare Part D, effective January 2023. The law did not extend that cap to Americans with private insurance or to the uninsured. Bills to broaden the cap to all patients with private coverage have been introduced multiple times but have not cleared both the House and Senate.
Voluntary moves by manufacturers
In 2023, the three companies that dominate the U.S. insulin market — Eli Lilly, Novo Nordisk, and Sanofi — announced reductions to list prices on several insulin products and out-of-pocket caps of $35 a month for many patients. The companies cited affordability concerns; critics noted the moves came amid congressional scrutiny and changes to Medicaid rebate rules.
The case for a federal cap
Supporters argue that insulin is a century-old, life-sustaining drug used by 8.4 million Americans, and that no patient should ration doses because of cost. They point to lower prices abroad as evidence the U.S. market is not delivering competitive results, and say voluntary corporate pledges can be reversed at any time without a legal backstop.
The case against a federal cap
Opponents argue that government price controls can discourage research and investment, distort insurance markets, or shift costs onto premiums and taxpayers. Some contend that the recent manufacturer announcements and existing Medicare cap show the issue is being addressed without broader federal mandates, and that targeted aid for uninsured patients would be more efficient than a universal cap.
Where the debate goes next
Future congressional proposals could extend the $35 cap to private insurance, set limits on manufacturer list prices, or expand discount programs for the uninsured. State legislatures have also enacted their own copay caps for state-regulated insurance plans. Voters weighing the question are essentially deciding how much of insulin pricing should be set by markets, by private agreements, or by federal law.